- Home
- PRFX vs VRAX Comparison
PRFX vs VRAX Comparison
Compare PRFX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRFX | VRAX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRFX | VRAX |
|---|---|---|
| Price | $1.96 | $0.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 329.5K | ★ 13.9M |
| Earning Date | 03-26-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.10 |
| 52 Week High | $3.71 | $1.18 |
Technical Indicators
Market Signals| Indicator | PRFX | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 41.89 |
| Support Level | $1.80 | $0.12 |
| Resistance Level | $2.89 | $0.18 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 10.33 | 17.63 |
Price Performance
Historical ComparisonAbout PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.